Galaxy银河|澳门官网·登录入口

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Porcine reproductive and respiratory syndrome virus neutralizing antibodies provide in vivo cross-protection to PRRSV1 and PRRSV2 viral challenge.

Virus Res.. 2018; 
RobinsonSally R,RaheMichael C,GrayDiem K,MartinsKyra V,MurtaughMicha
Products/Services Used Details Operation
Peptide Synthesis Six linear peptides, one each from GP2 and E, and two each from GP3 and GP4, were synthesized by GenScript (Piscataway, NJ). Based on testing at GenScript, peptides were solubilized to 1 mg/ml in either 0.1M PBS, pH 7.4 (GP2, E, GP4a), N-methyl-2-pyrrolidone (NMP) (GP3a, GP3b), or dimethyl sulfoxide (DMSO) (GP4b). Get A Quote

摘要

Vaccine control and prevention of porcine reproductive and respiratory syndrome (PRRS), the most important disease of swine, is difficult to achieve. However, the discovery of broadly neutralizing antibody activity against porcine reproductive and respiratory syndrome virus (PRRSV) under typical field conditions opens the door to new immunologic approaches for robust protection. We show here that passive administration of purified immunoglobulins with neutralizing antibodies reduced PRRSV2 infection by up to 96%, and PRRSV1 infection by up to 87%, whereas immune immunoglobulins lacking neutralizing activity had no effect on viral infection. Hence, immune competence of passive immunoglobulin transfer... More

关键词

Cross-protection,Neutralizing antibodies,Neutralizing epitope,PRRSV,Passive transfer,S
XML 地图